Reaxa spins-out ADC purification technology business

Pharma catalyst technologies specialist Reaxa is divesting its antibody drug purification technology business to become ADC Biotechnology Ltd. (ADCB).

Pharma catalyst technologies specialist Reaxa is divesting its antibody drug purification technology business to become ADC Biotechnology Ltd. (ADCB). Using new process technology, the company aims to deliver significant reduction in manufacturing costs for the new generation of “magic bullet” cancer drugs based on antibodies.

With background IP licensed exclusively from Reaxa, and a wider heritage in protein, peptide and DNA fragment technology, ADCB plans to have a prototype purification system licence-ready within two years.

ADCB is based in North Wales, at the Technium OpTIC incubator on St. Asaph Business Park.

Antibody-Drug-Conjugates (ADCs) are the “smart munitions” of anti-cancer technology. Antibodies act as carriers for chemotherapy drugs, targeting and entering specific cancer cells prior to ADC degradation to release drug payload.

ADC platform technologies are concentrated across a few major biopharma players, with the first ADC drug awaitin